[go: up one dir, main page]

AP567A - Combined vaccines comprising hepatitis B surface antigen and other antigens. - Google Patents

Combined vaccines comprising hepatitis B surface antigen and other antigens. Download PDF

Info

Publication number
AP567A
AP567A APAP/P/1993/000530A AP9300530A AP567A AP 567 A AP567 A AP 567A AP 9300530 A AP9300530 A AP 9300530A AP 567 A AP567 A AP 567A
Authority
AP
ARIPO
Prior art keywords
vaccine
hbsag
hepatitis
adsorbed
antigens
Prior art date
Application number
APAP/P/1993/000530A
Other languages
English (en)
Other versions
AP9300530A0 (en
Inventor
Jean Petre
Original Assignee
Smithkline Beecham Biologicals S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26300928&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP567(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB929211081A external-priority patent/GB9211081D0/en
Priority claimed from GB929213308A external-priority patent/GB9213308D0/en
Application filed by Smithkline Beecham Biologicals S A filed Critical Smithkline Beecham Biologicals S A
Publication of AP9300530A0 publication Critical patent/AP9300530A0/xx
Application granted granted Critical
Publication of AP567A publication Critical patent/AP567A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
APAP/P/1993/000530A 1992-05-23 1993-05-20 Combined vaccines comprising hepatitis B surface antigen and other antigens. AP567A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929211081A GB9211081D0 (en) 1992-05-23 1992-05-23 Vaccines
GB929213308A GB9213308D0 (en) 1992-06-23 1992-06-23 Vaccine

Publications (2)

Publication Number Publication Date
AP9300530A0 AP9300530A0 (en) 1993-07-31
AP567A true AP567A (en) 1996-11-25

Family

ID=26300928

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1993/000530A AP567A (en) 1992-05-23 1993-05-20 Combined vaccines comprising hepatitis B surface antigen and other antigens.

Country Status (30)

Country Link
US (1) US6013264A (fr)
EP (4) EP0835663B1 (fr)
JP (1) JP3626996B2 (fr)
KR (1) KR100287083B1 (fr)
CN (2) CN1136918C (fr)
AP (1) AP567A (fr)
AT (2) ATE444079T1 (fr)
AU (5) AU4315693A (fr)
CA (1) CA2136429C (fr)
CY (1) CY2614B2 (fr)
CZ (1) CZ283910B6 (fr)
DE (4) DE69334297D1 (fr)
DK (2) DK0835663T3 (fr)
ES (2) ES2334181T3 (fr)
FI (1) FI945483L (fr)
HU (1) HU220236B (fr)
IL (1) IL105770A (fr)
LU (2) LU91658I2 (fr)
MA (1) MA22894A1 (fr)
MX (1) MX9302982A (fr)
MY (1) MY110665A (fr)
NO (1) NO309675B1 (fr)
NZ (1) NZ253065A (fr)
PT (1) PT835663E (fr)
RU (1) RU2160120C2 (fr)
SG (1) SG48365A1 (fr)
SI (1) SI9300271A (fr)
SK (1) SK280702B6 (fr)
UA (1) UA40596C2 (fr)
WO (1) WO1993024148A1 (fr)

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9503863D0 (en) * 1995-02-25 1995-04-19 Smithkline Beecham Biolog Vaccine compositions
US6696065B1 (en) 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
FR2734484B1 (fr) 1995-05-24 1997-06-27 Pasteur Merieux Serums Vacc Composition vaccinale liquide et procede de fabrication
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
AU696338B2 (en) 1995-06-23 1998-09-10 Smithkline Beecham Biologicals (Sa) A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
IL127847A (en) * 1996-07-02 2004-06-01 Connaught Lab Polio-karma vaccine vaccines, valuable pertussis
US20010014331A1 (en) 1996-11-07 2001-08-16 Smithkline Beecham Biologicals S.A. Acellular pertussis vaccine with diphthriae-and tetanus-toxoids
GB9623233D0 (en) * 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
CU22629A1 (es) * 1997-03-06 2000-12-22 Ct Ingenieria Genetica Biotech Formulaciones inmunopotenciadoras para uso vacunal
JP2002508748A (ja) * 1997-05-01 2002-03-19 カイロン コーポレイション アジュバントとしてのウイルス様粒子の使用
DK1028750T3 (da) * 1997-09-15 2006-05-22 Sanofi Pasteur Msd Fremgangsmåde til fremstilling af multivalente vacciner
NZ506602A (en) * 1998-03-09 2003-02-28 Smithkline Beecham Biolog S Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii
GB9806456D0 (en) * 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US20030049268A1 (en) 1998-05-01 2003-03-13 Smithkline Beecham Biologicals S.A. Novel composition
GB9809507D0 (en) * 1998-05-01 1998-07-01 Smithkline Beecham Biolog Novel composition
RU2130779C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа Научно-производственная компания "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка и дифтерии
RU2130778C1 (ru) * 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
AT408615B (de) * 1998-09-15 2002-01-25 Immuno Ag Neue influenzavirus-impfstoffzusammensetzung
SI1126876T1 (sl) 1998-10-16 2007-08-31 Glaxosmithkline Biolog Sa Adjuvantni sistemi in vakcine
CN1053590C (zh) * 1998-10-19 2000-06-21 卫生部长春生物制品研究所 冻干甲型肝炎减毒活疫苗及其保护剂
CU22871A1 (es) 1998-12-02 2003-10-21 Ct Ingenieria Genetica Biotech Formulaciones conteniendo partículas semejantes a virus como inmunopotenciadores por vía mucosal
US6974581B1 (en) * 1998-12-15 2005-12-13 Aventis Pasteur Limited Multi-component vaccine comprising at least two antigens from haemophilus influenzae to protect against disease
US7098309B2 (en) * 1998-12-23 2006-08-29 Merck & Co., Inc. Recombinant hepatitis B surface antigen
US7172762B1 (en) * 1999-01-29 2007-02-06 Pfizer Inc. Erysipelothrix rhusiopathiae antigens and vaccine compositions
GB9923060D0 (en) 1999-09-29 1999-12-01 Chiron Spa Vaccine
GB9928196D0 (en) 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
EP2279748A1 (fr) 2000-06-29 2011-02-02 SmithKline Beecham Biologicals S.A. Composition vaccinale multivalente
KR100385711B1 (ko) * 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
AP1897A (en) 2001-01-23 2008-10-10 Aventis Pasteur Multivalent Meningococcal polysaccharide-Protein Conjugate Vaccine.
AU2007200116A1 (en) * 2001-04-03 2007-02-01 Glaxosmithkline Biologicals S.A. Vaccine composition
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
CA2452720C (fr) * 2001-07-26 2012-04-17 Chiron S.R.L. Vaccins comprenant des adjuvants aluminium et histidine
IL145926A0 (en) * 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
CU23031A1 (es) * 2002-01-24 2005-02-23 Ct Ingenieria Genetica Biotech Antigeno de superficie del virus de la hepatitis b como inmunopotenciador mucosal, formulaciones resultantes
CA2480690A1 (fr) * 2002-03-28 2003-10-09 Brenntag Biosector A/S Compositions de vaccins a proteines/adn combines
GB0223355D0 (en) * 2002-10-08 2002-11-13 Chiron Spa Vaccine
JP4579156B2 (ja) 2002-11-01 2010-11-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原組成物
EP2191844B1 (fr) 2003-01-30 2014-03-05 Novartis AG Vaccins injectables contre les multiples serogroupes du meningocoque
RU2238105C1 (ru) * 2003-03-14 2004-10-20 Закрытое акционерное общество научно-производственная компания "Комбиотех" Рекомбинантная вакцина для профилактики вирусного гепатита в (варианты)
RU2233673C1 (ru) * 2003-03-31 2004-08-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Комбинированная вакцина для иммунопрофилактики коклюша, дифтерии, столбняка и вирусного гепатита в и д
RU2233672C1 (ru) * 2003-03-31 2004-08-10 Закрытое акционерное общество научно-производственная компания "Комбиотех" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в и д, столбняка и дифтерии
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2885040C (fr) 2003-10-02 2018-10-30 Novartis Vaccines And Diagnostics S.R.L. Vaccins liquides contre de multiples serogroupes meningococciques
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
CN1984679B (zh) 2004-06-04 2013-05-15 美国政府健康及人类服务部 制备免疫原性结合物的方法
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
GB0505996D0 (en) 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
SG175456A1 (en) 2005-04-18 2011-11-28 Novartis Vaccines & Diagnostic Expressing hepatitis b virus surface antigen for vaccine preparation
KR101408113B1 (ko) 2005-06-27 2014-06-16 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신 제조 방법
GB0517719D0 (en) * 2005-08-31 2005-10-05 Chiron Srl Vaccines containing pili
EP1931380A2 (fr) 2005-09-01 2008-06-18 Novartis Vaccines and Diagnostics GmbH & Co. KG Vaccination multiple comprenant des meningocoques du serogroupe c
GB0522765D0 (en) * 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
EP1862176A1 (fr) * 2006-05-31 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Procédé de production de composition vaccinale
EP1862177A1 (fr) * 2006-06-01 2007-12-05 Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH Procédé de production de composition vaccinale
GB0616226D0 (en) * 2006-08-15 2006-09-27 Novartis Ag Processes
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
GB0617602D0 (en) * 2006-09-07 2006-10-18 Glaxosmithkline Biolog Sa Vaccine
HRP20120557T1 (hr) 2006-09-07 2012-07-31 GlaxoSmithKline@Biologicals@s@a Kombinirano cjepivo sa smanjenim količinama antigena poliovirusa
EA200970731A1 (ru) * 2007-02-07 2010-02-26 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Рекомбинантные антигены цитомегаловируса человека (hcmv)
MX2009011837A (es) 2007-05-02 2010-04-22 Glaxosmithkline Biolog Sa Vacuna.
CU23679A1 (es) * 2007-10-30 2011-07-11 Ct Ingenieria Genetica Biotech Variantes de pertactinas para uso vacunal
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
PE20100366A1 (es) 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas composiciones de vacuna con tos ferina acelular asi como el metodo para su elaboracion
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
IT1398927B1 (it) 2009-06-25 2013-03-28 Consorzio Interuniversitario Per Lo Sviluppo Dei Sistemi A Grande Interfase Csgi Espressione batterica di un gene artificiale per la produzione di crm197 e derivati.
GB0917647D0 (en) 2009-10-08 2009-11-25 Glaxosmithkline Biolog Sa Expression system
WO2012020326A1 (fr) 2010-03-18 2012-02-16 Novartis Ag Vaccins adjuvantés contre le méningocoque de sérogroupe b
FR2966044B1 (fr) 2010-10-18 2012-11-02 Sanofi Pasteur Procede de conditionnement d'un vaccin contenant un adjuvant d'aluminium
NZ611176A (en) 2010-12-02 2015-07-31 Bionor Immuno As Peptide scaffold design
CN103442730B (zh) 2011-01-05 2016-08-17 巴拉特生物技术国际有限公司 组合七价疫苗
CA2821995C (fr) 2011-01-06 2019-02-12 Bionor Immuno As Peptides monomeres et multimeres immunogenes contre le vih
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
SG194886A1 (en) * 2011-05-11 2013-12-30 Riesbeck Healthcare Sweden Ab Protein f - a novel haemophilus influenzae adhesin with laminin and vitronectin binding properties
WO2013049535A2 (fr) 2011-09-30 2013-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Vaccin antigrippal
RU2465316C1 (ru) * 2011-10-05 2012-10-27 Общество с ограниченной ответственностью "ГРИТВАК" Штамм бактерий haemophilus influenzae в №326, стабильный продуцент капсульного полисахарида
EP2592137A1 (fr) 2011-11-11 2013-05-15 Novartis AG Support de fermentation sans composants dérivés d'animaux pour la production des toxoïdes diphtériques adaptées à l'utilisation du vaccin humain
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
FR2985663B1 (fr) * 2012-01-17 2015-03-27 Sanofi Pasteur Procede de formulation d'un vaccin contenant au moins deux antigenes susceptibles de s'adsorber sur de l'oxy hydroxyde d'aluminium
US9475848B2 (en) 2012-02-01 2016-10-25 Glaxosmithkline Biologicals S.A. Fermentation process for producing a virulence factor from bordetella
CN104159603A (zh) * 2012-03-08 2014-11-19 诺华股份有限公司 带有tlr4激动剂的联合疫苗
CA2874923C (fr) 2012-06-06 2021-08-31 Bionor Immuno As Peptides issus de proteines virales pour l'utilisation en tant qu'immunogenes et reactifs de dosage
SG11201500573RA (en) 2012-08-06 2015-02-27 Glaxosmithkline Biolog Sa Method for eliciting in infants an immune response against rsv and b. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013328548A1 (en) 2012-10-12 2015-05-07 Glaxosmithkline Biologicals Sa Non-cross-linked acellular pertussis antigens for use in combination vaccines
KR102236498B1 (ko) 2013-03-08 2021-04-06 얀센 백신스 앤드 프리벤션 비.브이. 무세포 백일해 백신
US9993534B2 (en) 2013-03-12 2018-06-12 Wisconsin Alumni Research Foundation Method of treating fungal infection
CA2919773A1 (fr) 2013-08-05 2015-02-12 Glaxosmithkline Biologicals S.A. Compositions immunogenes en combinaison
AR101256A1 (es) 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
WO2017048038A1 (fr) * 2015-09-16 2017-03-23 Lg Life Sciences Ltd. Composition de vaccin combinée pour administration multiple
WO2018067582A2 (fr) 2016-10-03 2018-04-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogènes de peptides de fusion env du vih-1 et leur utilisation
WO2018081832A1 (fr) 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fragments peptidiques de filovirus et leurs utilisations
WO2018176031A1 (fr) 2017-03-24 2018-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Domaines externes modifiés masqués par le glycane du vih-1, gp120, et leur utilisation
CA3070039A1 (fr) 2017-07-18 2019-01-24 Serum Institute Of India Pvt Ltd. Composition immunogene a stabilite amelioree, immunogenicite amelioree et moindre reactogenicite, et procede de preparation de cette derniere
EP3697440A1 (fr) 2017-10-16 2020-08-26 The United States of America, as represented by the Secretary, Department of Health and Human Services Protéines d'enveloppe recombinées du vih-1 et leur utilisation
WO2020043874A1 (fr) 2018-08-31 2020-03-05 Glaxosmithkline Biologicals Sa Vaccin conjugué contre haemophilus influenzae utilisant une vésicule de membrane externe de bordetella
US12053519B2 (en) 2018-09-23 2024-08-06 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HIV-1 Env fusion peptide nanoparticle carrier conjugates and their use
JOP20190242A1 (ar) 2018-10-12 2020-04-12 Serum Institute Of India Pvt Ltd تركيبة لقاح توليفي تشمل فيروس شلل الأطفال ذو جرعة مخفّضة خاملة التنشيط وطريقة لتحضيرها
US12162910B2 (en) 2018-10-22 2024-12-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant gp120 protein with V1-loop deletion
GB2619625B (en) 2019-05-20 2024-04-03 Soligenix Inc Compositions and Methods of Manufacturing Trivalent Filovirus Vaccines
US12210017B2 (en) 2020-01-08 2025-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptides representing epitopes from filoviruses
WO2021160887A1 (fr) 2020-02-14 2021-08-19 Immunor As Vaccin contre le coronavirus
WO2021176409A1 (fr) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Combinaison de conservateurs pour composition de vaccin
US12268738B2 (en) 2021-04-20 2025-04-08 Km Biologics Co., Ltd. Liquid six combined vaccine composition
US20240277829A1 (en) 2021-08-03 2024-08-22 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Hiv-1 vaccination and samt-247 microbicide to prevent hiv-1 infection
EP4169513A1 (fr) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Composition d'adjuvant comprenant des agonistes du sting
WO2023192835A1 (fr) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ectodomaines de l'enveloppe du vih-1 recouverts d'une base et leur utilisation
WO2024249626A1 (fr) 2023-05-30 2024-12-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Trimères en tandem triple de l'enveloppe du vih-1 et leur utilisation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339667A2 (fr) * 1988-04-28 1989-11-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vaccin combiné, adjuvanté et pour l'hépatite A et l'hépatite B

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6013718A (ja) * 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) * 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4624918A (en) * 1984-07-09 1986-11-25 Genentech, Inc. Purification process for hepatitis surface antigen and product thereof
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
AP56A (en) 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
EP0304578B1 (fr) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide contenant l'antigène de surface de l'hépatite B
ATE105858T1 (de) 1987-07-17 1994-06-15 Rhein Biotech Ges Fuer Biotech Dna-moleküle, die für fmdh-kontrollabschnitte und strukturgene für ein protein mit fmdh-aktivität kodieren, sowie deren anwendung.
SG48175A1 (en) 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
EP0427462B1 (fr) 1989-11-06 1996-02-14 SMITHKLINE BEECHAM BIOLOGICALS (S.A.), formerly SMITHKLINE BIOLOGICALS (S.A.) Procédé
JP3035712B2 (ja) 1990-02-12 2000-04-24 スミスクライン ビーチャム バイオロジカルズ（エス ア） 新規なワクチンおよびそのための方法
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
AU9052091A (en) * 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
CA2067003A1 (fr) 1991-04-29 1992-10-30 Peter J. Kniskern Vaccin mutant de variante d'antigene de surface d'hbv
EP0533492A3 (en) * 1991-09-18 1994-08-10 Amgen Inc A hepatitis b vaccine formulation incorporating a bile acid salt
CZ289476B6 (cs) * 1993-03-23 2002-01-16 Smithkline Beecham Biologicals (S.A.) Očkovací přípravek a způsob jeho výroby
AU696338B2 (en) 1995-06-23 1998-09-10 Smithkline Beecham Biologicals (Sa) A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
RU2130778C1 (ru) 1998-07-31 1999-05-27 Акционерное общество закрытого типа НПК "Комбиотех Лтд" Комбинированная вакцина для иммунопрофилактики вирусного гепатита в, столбняка, дифтерии и коклюша
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
KR100401423B1 (ko) 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0339667A2 (fr) * 1988-04-28 1989-11-02 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Vaccin combiné, adjuvanté et pour l'hépatite A et l'hépatite B

Also Published As

Publication number Publication date
EP2156845A1 (fr) 2010-02-24
UA40596C2 (uk) 2001-08-15
RU2160120C2 (ru) 2000-12-10
AU709406C (en) 2004-04-08
DE69319728T2 (de) 1999-02-04
KR100287083B1 (ko) 2001-04-16
HU9403366D0 (en) 1995-02-28
SK280702B6 (sk) 2000-06-12
EP2289548A2 (fr) 2011-03-02
FI945483A0 (fi) 1994-11-22
HK1011290A1 (en) 1999-07-09
CZ289294A3 (en) 1995-09-13
US6013264A (en) 2000-01-11
AU2007201162A1 (en) 2007-04-19
LU91659I2 (fr) 2010-05-03
CN1136918C (zh) 2004-02-04
DK0835663T3 (da) 2010-02-01
ATE444079T1 (de) 2009-10-15
KR950701822A (ko) 1995-05-17
FI945483A7 (fi) 1995-01-20
IL105770A (en) 1998-08-16
AU709406B2 (en) 1999-08-26
NZ253065A (en) 1996-10-28
NO944475D0 (no) 1994-11-22
HU220236B (hu) 2001-11-28
IL105770A0 (en) 1993-09-22
CZ283910B6 (cs) 1998-07-15
AU1648097A (en) 1997-05-29
DE69334297D1 (de) 2009-11-12
AU4315693A (en) 1993-12-30
PT835663E (pt) 2010-01-04
RU94046145A (ru) 1997-03-27
HUT71791A (en) 1996-02-28
WO1993024148A1 (fr) 1993-12-09
EP0835663A3 (fr) 1999-03-03
SI9300271A (en) 1993-12-31
NO309675B1 (no) 2001-03-12
MX9302982A (es) 1993-12-01
EP2289548A3 (fr) 2012-08-08
DE122010000015I1 (de) 2010-07-08
MA22894A1 (fr) 1993-12-31
HK1021142A1 (en) 2000-06-02
EP0642355A1 (fr) 1995-03-15
CN1085450A (zh) 1994-04-20
CA2136429A1 (fr) 1993-12-09
CN1623602A (zh) 2005-06-08
MY110665A (en) 1999-01-30
AP9300530A0 (en) 1993-07-31
AU2010200249A1 (en) 2010-02-11
EP0835663B1 (fr) 2009-09-30
AU5062902A (en) 2002-08-08
CA2136429C (fr) 2001-12-11
ES2334181T3 (es) 2010-03-05
AU2010200249B2 (en) 2012-01-12
EP0642355B1 (fr) 1998-07-15
EP0835663A2 (fr) 1998-04-15
LU91658I2 (fr) 2010-05-03
JP3626996B2 (ja) 2005-03-09
CN1313152C (zh) 2007-05-02
NO944475L (no) 1995-01-18
SK142194A3 (en) 1995-08-09
DK0642355T3 (da) 1998-11-30
ATE168271T1 (de) 1998-08-15
FI945483L (fi) 1995-01-20
DE122010000016I1 (de) 2010-07-08
ES2118963T3 (es) 1998-10-01
SG48365A1 (en) 1998-04-17
AU785433B2 (en) 2007-05-31
CY2614B2 (en) 2012-01-25
DE69319728D1 (de) 1998-08-20
JPH07508267A (ja) 1995-09-14

Similar Documents

Publication Publication Date Title
AP567A (en) Combined vaccines comprising hepatitis B surface antigen and other antigens.
EP2066344B2 (fr) Vaccin combiné du virus de poliomyelite inactivé
JP4233113B2 (ja) 多糖類抗原−キャリア蛋白接合体および遊離キャリア蛋白を有してなるワクチン
BRPI9712917B1 (pt) composição de vacina compreendendo toxóides diftérico, tetânico e pertussis.
AU2012202099A1 (en) Combined vaccines comprising hepatitis B surface antigen and other antigens
US8623380B2 (en) Acellular pertussis vaccine with diphthriae- and tetanus-toxoids
RU2287344C2 (ru) Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека
HK1011290B (en) Combined vaccines comprising hepatitis b surface antigen and other antigens
HK1147950A (en) Combined vaccines comprising hepatitis b surface antigen and other antigens
HK1137937A (en) Combined vaccines comprising hepatitis b surface antigen and other antigens
HK1021142B (en) Combined vaccines comprising hepatitis b surface antigen and other antigens